Arterial Stiffness Tested by Pulse Wave Velocity and Augmentation Index for Cardiovascular Risk Stratification in Antiphospholipid Syndrome

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2023 Jun 9

PMID 37294733

Authors

Gerasimos Evangelatos

George Konstantonis

Nikolaos Tentolouris

Petros P Sfikakis

Maria G Tektonidou

Affiliations

Soon will be listed here.

Abstract

Objectives: Cardiovascular disease is a major cause of morbidity and mortality in Antiphospholipid syndrome (APS). Arterial stiffness (ArS) has emerged as a predictor of future cardiovascular events in the general population. We aimed to assess ArS in patients with thrombotic APS versus diabetes mellitus (DM) and healthy controls (HC) and identify predictors of increased ArS in APS.

Methods: ArS was evaluated by carotid-femoral pulse wave velocity (cfPWV) and augmentation index normalized to 75 beats/min (AIx@75) using the SphygmoCor device. Participants also underwent carotid/femoral ultrasound for atherosclerotic plaque detection. We used linear regression to compare ArS measures among groups and assess ArS determinants in the APS group.

Results: We included 110 patients with APS (70.9% female, mean age 45.4 years), 110 DM patients and 110 HC, all age/sex matched. After adjustment for age, sex, cardiovascular risk factors and plaque presence, APS patients exhibited similar cfPWV [β = -0.142 (95% CI -0.514, 0.230), p = 0.454] but increased AIx@75 [β = 4.525 (95% CI 1.372, 7.677), p = 0.005] compared with HC and lower cfPWV (p < 0.001) but similar AIx@75 (p = 0.193) versus DM patients. In the APS group, cfPWV was independently associated with age [β = 0.056 (95% CI 0.034, 0.078), p < 0.001], mean arterial pressure (MAP) [β = 0.070 (95% CI 0.043, 0.097), p < 0.001], atherosclerotic femoral plaques [β = 0.732 (95% CI 0.053, 1.411), p = 0.035] and anti-β2-glycoprotein I IgM positivity [β = 0.696 (95% CI 0.201, 1.191), p = 0.006]. AIx@75 was associated with age [β = 0.334 (95% CI 0.117, 0.551), p = 0.003], female sex [β = 7.447 (95% CI 2.312, 12.581), p = 0.005] and MAP [β = 0.425 (95% CI 0.187, 0.663), p = 0.001].

Conclusion: APS patients exhibit elevated AIx@75 vs HC and similar to DM patients, indicating enhanced arterial stiffening in APS. Given its prognostic value, ArS evaluation may help to improve cardiovascular risk stratification in APS.

Citing Articles

Navigating antiphospholipid syndrome: from personalized therapies to cutting-edge research.

Kortright-Maldonado K, Reyes-Torres B, Cabrera-Lopez L, Rodriguez-Henriquez P, Tenorio-Aguirre E, Martinez-Sanchez F Rheumatol Adv Pract. 2025; 9(1):rkaf005.

PMID: 39846052 PMC: 11751690. DOI: 10.1093/rap/rkaf005.

Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls.

Evangelatos G, Tentolouris N, Sfikakis P, Tektonidou M Rheumatology (Oxford). 2024; 64(2):836-841.

PMID: 38321577 PMC: 11781572. DOI: 10.1093/rheumatology/keae097.

Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations.

Gaspar P, Sciascia S, Tektonidou M Rheumatology (Oxford). 2024; 63(SI):SI24-SI36.

PMID: 38320589 PMC: 10846913. DOI: 10.1093/rheumatology/kead571.

References

Meroni P, Borghi M, Grossi C, Chighizola C, Durigutto P, Tedesco F . Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nat Rev Rheumatol. 2018; 14(7):433-440. DOI: 10.1038/s41584-018-0032-6. View

Williams B, Lacy P, Thom S, Cruickshank K, Stanton A, Collier D . Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113(9):1213-25. DOI: 10.1161/CIRCULATIONAHA.105.595496. View

Evangelatos G, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis P, Tektonidou M . Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study. Rheumatology (Oxford). 2021; 61(8):3408-3413. DOI: 10.1093/rheumatology/keab882. View

Di Minno M, Emmi G, Ambrosino P, Scalera A, Tufano A, Cafaro G . Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: A cross-sectional study. Int J Cardiol. 2018; 274:1-6. DOI: 10.1016/j.ijcard.2018.06.010. View

Angoff R, Mosarla R, Tsao C . Aortic Stiffness: Epidemiology, Risk Factors, and Relevant Biomarkers. Front Cardiovasc Med. 2021; 8:709396. PMC: 8606645. DOI: 10.3389/fcvm.2021.709396. View

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

Panopoulos S, Drosos G, Konstantonis G, Sfikakis P, Tektonidou M . Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE. Lupus Sci Med. 2023; 10(1). PMC: 9990693. DOI: 10.1136/lupus-2022-000864. View

Kim H, Kim S . Pulse Wave Velocity in Atherosclerosis. Front Cardiovasc Med. 2019; 6:41. PMC: 6465321. DOI: 10.3389/fcvm.2019.00041. View

Sakurai M, Yamakado T, Kurachi H, Kato T, Kuroda K, Ishisu R . The relationship between aortic augmentation index and pulse wave velocity: an invasive study. J Hypertens. 2007; 25(2):391-7. DOI: 10.1097/HJH.0b013e3280115b7c. View

10.

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

11.

Benhamou Y, Bellien J, Armengol G, Brakenhielm E, Adriouch S, Iacob M . Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol. 2014; 66(11):3210-20. DOI: 10.1002/art.38785. View

12.

Di Minno M, Scalera A, Tufano A, Ambrosino P, Bettiol A, Silvestri E . The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. Atherosclerosis. 2018; 278:60-65. DOI: 10.1016/j.atherosclerosis.2018.09.010. View

13.

Parra S, Lopez-Dupla M, Ibarretxe D, de Las Heras M, Amigo N, Catala A . Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti-β -Glycoprotein I and Small Dense High-Density Lipoprotein Particles. Arthritis Care Res (Hoboken). 2018; 71(1):116-125. DOI: 10.1002/acr.23594. View

14.

Cervera R, Serrano R, Pons-Estel G, Ceberio-Hualde L, Shoenfeld Y, de Ramon E . Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014; 74(6):1011-8. DOI: 10.1136/annrheumdis-2013-204838. View

15.

Touboul P, Hennerici M, Meairs S, Adams H, Amarenco P, Bornstein N . Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany,.... Cerebrovasc Dis. 2012; 34(4):290-6. PMC: 3760791. DOI: 10.1159/000343145. View

16.

Mceniery C, Spratt M, Munnery M, Yarnell J, Lowe G, Rumley A . An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. Hypertension. 2010; 56(1):36-43. DOI: 10.1161/HYPERTENSIONAHA.110.150896. View

17.

Bolla E, Tentolouris N, Sfikakis P, Tektonidou M . Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus. Lupus Sci Med. 2021; 8(1). PMC: 8685967. DOI: 10.1136/lupus-2021-000579. View

18.

Jurcut C, Caraiola S, Nitescu D, Jurcut R, Giusca S, Baicus C . Subclinical vascular disease in patients with systemic lupus erythematosus: the additive deleterious effect of the antiphospholipid syndrome. Joint Bone Spine. 2012; 79(6):628-9. DOI: 10.1016/j.jbspin.2012.01.014. View

19.

Soltesz P, Der H, Veres K, Laczik R, Sipka S, Szegedi G . Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford). 2008; 47(11):1628-34. DOI: 10.1093/rheumatology/ken349. View

20.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View